ANAHEIM, Calif.—Fifteen percent of older men managed with watchful waiting for low-risk prostate tumors detected by PSA screening will die from the malignancy in 10 years, despite a high death rate from competing causes, a study found.
ANAHEIM, Calif.—Prostate cancers found as a result of PSA screening are less likely to exhibit extracapsular extension and positive surgical margins after radical prostatectomy than tumors found in a non-screened population, despite similar PSA levels, data show.
For some men with localized prostate cancer, active surveillance has emerged in recent years as a viable management option.
Contrary to what is commonly thought, the risk of having a positive repeat prostate biopsy is no lower for men with a fluctuating PSA level than it is for those with a steady or steadily increasing PSA level.
The most widespread nondermatologic malignancy in men, prostate cancer afflicts one in six American males and kills one in 34. Growing public awareness, an aging population, and increased PSA screening has led to greater detection of early-stage disease.